Overview of Dr. Yu
Dr. Evan Yu is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance, UW Medicine/Harborview Medical Center, and UW Medicine/University of Washington Medical Center. He received his medical degree from University of Washington School of Medicine and has been in practice 19 years. Dr. Yu accepts several types of health insurance, listed below. He is one of 32 doctors at UW Medicine/Harborview Medical Center and one of 136 doctors at UW Medicine/University of Washington Medical Center who specialize in Oncology.
Office
Ambulatory Clinic
825 Eastlake Avenue East
Seattle, WA 98109- Is this information wrong?
Education & Training
- Brigham and Women's HospitalFellowship, Hematology/Oncology, 2001 - 2004
- Stanford UniversityResidency, Internal Medicine, 1998 - 2001
- University of Washington School of MedicineClass of 1998
Certifications & Licensure
WA State Medical License 2004 - 2021- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 01Aragon-ching J.,Asch A.,Beck J.,Bellmunt J.,Burke J.,Cultrera J.,Dichmann R.,Doshi G.,Drakaki A.,Flaig T.,Hainsworth J.,Hancock M.,Herms B.,Kendall S.,Kohli M.,Lawler W.,Lowe T.,Matrana M.,Mcknight J.,Oje...
- A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard FDA Approved Therapy With Sipuleucel-T (Provenge®) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cance Start of enrollment: 2014 Aug 01Fong, L.,Yu, E.Y.,Ferrari, A.,Seigne, J.D.,Kucuk, O.
- Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer Start of enrollment: 2014 Jul 01Yu, E.
- Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer Start of enrollment: 2010 Dec 01Yu, E.
- Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel Start of enrollment: 2010 Oct 01Yu, E.Y.,Nelson, P.S.,Beer, T.,Beer, T.M.
- Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases Start of enrollment: 2009 Sep 01Yu, E.
- Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer Start of enrollment: 2006 Dec 01Yu, E.
- Join now to see all
Publications & Presentations
PubMed
- Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.Laura S. Graham, Lawrence D. True, Roman Gulati, George R. Schade, Jonathan L. Wright, Petros Grivas, Todd Yezefski, Katie Nega, Katerina Alexander, Wen‐Min Hou, Evan ...> ;The Prostate. 2021 Mar 23
- BiTE-ing into prostate cancer with bispecific T cell engagersNikhil V Kamat, Evan Y. Yu, John K. Lee> ;Clinical Cancer Research. 2021 Mar 11
- Disparities in Cancer Care and the Asian American PopulationRichard J. Lee, Ravi A. Madan, Jayoung Kim, Edwin M. Posadas, Evan Y. Yu> ;Oncologist. 2021 Mar 8
- Join now to see all
Journal Articles
- Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing InterferenceMichael T Schweizer, Petros Grivas, Heather H Cheng, Evan Y Yu, JAMA Oncology
Lectures
- Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYN...2019 ASCO Annual Meeting - 6/1/2019
- A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carci...2019 ASCO Annual Meeting - 6/1/2019
- Targeted Therapies in Advanced Urothelial Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Patient-Reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer - Neeraj AgarwalJune 5th, 2020- Sequencing Treatments in Metastatic Prostate Cancer - Evan YuJune 5th, 2020
Neoadjuvant Systemic Therapy for Prostate Cancer: If a PUNCH Is Good, What Will It Take to Score a Knockout?February 7th, 2020- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Seattle Cancer Care AllianceSeattle, Washington
UW Medicine/Harborview Medical CenterSeattle, Washington
UW Medicine/University of Washington Medical CenterSeattle, Washington
Insurance Accepted
- Aetna Choice POS II
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Choice
Great West PPOHealth Net Oregon PPO
Multiplan PPO
ODS Network
Premera BCBS Heritage & Heritage Plus 1
Providence Health System Personal Option
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
